Switch Therapeutics

Switch Therapeutics is an emerging biotechnology company that has pioneered a new class of drugs combining nucleic acid nanotechnology and RNA interference (RNAi) science to address a range of diseases affecting the central nervous system and systemic indications. The company’s novel gene knockdown approach, the CASi (Conditionally Activated siRNA) platform, is based on technology developed by renowned researchers in RNA and drug development from Caltech, Harvard Medical School, and City of Hope. CASi combines the advantageous properties of single-stranded and double-stranded RNA within a single molecule, enabling cell-selective RNAi activity.